Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib open-label dose-escalation and expansion study of RO7009789 combined with vanucizumab or bevacizumab in metastatic solid tumors
NL-OMON47188Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of selicrelumab, faricimab and bevacizumab in Nonhematologic neoplasms, ovarian cancer, head and neck squamous cell carcinoma (HNSCC) and 1 more (2 arms), sponsored by Roche. Primary endpoints: Safety, Maximum tolerated dose and 5 more. Started May 2016; status: active, not recruiting.
02
Drugs
selicrelumabfaricimabbevacizumab
03
Conditions
Nonhematologic neoplasmsovarian cancerhead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47188.